ARTICLE | Company News
atugen, Novo Nordisk GeneBloc deal
January 8, 2002 8:00 AM UTC
Functional genomics company atugen (Berlin, Germany) will develop GeneBloc antisense oligonucleotides to inhibit expression of genetic targets selected by Novo Nordisk (NVO) under a 1-year deal. NVO t...